GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Inventories, Inventories Adjustments

HURA (TuHURA Biosciences) Inventories, Inventories Adjustments : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Inventories, Inventories Adjustments?

TuHURA Biosciences's Inventories, Inventories Adjustments for the quarter that ended in Sep. 2024 was $0.00 Mil.


TuHURA Biosciences Inventories, Inventories Adjustments Historical Data

The historical data trend for TuHURA Biosciences's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Inventories, Inventories Adjustments Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Inventories, Inventories Adjustments
- - -

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24
Inventories, Inventories Adjustments Get a 7-Day Free Trial - - - - -

TuHURA Biosciences Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


TuHURA Biosciences Business Description

Industry
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.